[go: up one dir, main page]

NO974502L - Intercellulært domene av HER-2/neu-protein for forhindring eller behandling av malignitet - Google Patents

Intercellulært domene av HER-2/neu-protein for forhindring eller behandling av malignitet

Info

Publication number
NO974502L
NO974502L NO974502A NO974502A NO974502L NO 974502 L NO974502 L NO 974502L NO 974502 A NO974502 A NO 974502A NO 974502 A NO974502 A NO 974502A NO 974502 L NO974502 L NO 974502L
Authority
NO
Norway
Prior art keywords
prevention
treatment
malignancy
neu protein
intercellular domain
Prior art date
Application number
NO974502A
Other languages
English (en)
Other versions
NO974502D0 (no
NO321941B1 (no
Inventor
Martin A Cheever
Mary L Disis
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NO974502D0 publication Critical patent/NO974502D0/no
Publication of NO974502L publication Critical patent/NO974502L/no
Publication of NO321941B1 publication Critical patent/NO321941B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G01N33/57557—
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19974502A 1995-03-31 1997-09-29 Blanding som omfatter et polypeptid, nukleinsyre som styrer ekspresjonen av polypeptidet og viral vektor, samt anvendelser derav for fremstilling av et medikament. NO321941B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/414,417 US5801005A (en) 1993-03-17 1995-03-31 Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
PCT/US1996/001689 WO1996030514A1 (en) 1995-03-31 1996-03-28 Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies

Publications (3)

Publication Number Publication Date
NO974502D0 NO974502D0 (no) 1997-09-29
NO974502L true NO974502L (no) 1997-11-27
NO321941B1 NO321941B1 (no) 2006-07-24

Family

ID=23641368

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19974502A NO321941B1 (no) 1995-03-31 1997-09-29 Blanding som omfatter et polypeptid, nukleinsyre som styrer ekspresjonen av polypeptidet og viral vektor, samt anvendelser derav for fremstilling av et medikament.
NO20061723A NO20061723L (no) 1995-03-31 2006-04-19 Intercellulaert domene av HER-2/neu-protein for forhindring eller behandling av malignitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20061723A NO20061723L (no) 1995-03-31 2006-04-19 Intercellulaert domene av HER-2/neu-protein for forhindring eller behandling av malignitet

Country Status (19)

Country Link
US (9) US5801005A (no)
EP (2) EP1418235A3 (no)
JP (2) JP4510147B2 (no)
KR (1) KR100554186B1 (no)
CN (3) CN1150318C (no)
AT (1) ATE299180T1 (no)
AU (1) AU708237B2 (no)
BR (1) BR9607889A (no)
CA (1) CA2216601C (no)
CZ (2) CZ296617B6 (no)
DE (1) DE69634912T2 (no)
DK (1) DK0817846T3 (no)
ES (1) ES2245783T3 (no)
HU (1) HUP9801826A3 (no)
NO (2) NO321941B1 (no)
NZ (1) NZ306616A (no)
PT (1) PT817846E (no)
RU (2) RU2236461C2 (no)
WO (1) WO1996030514A1 (no)

Families Citing this family (357)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ATE397061T1 (de) 1997-01-08 2008-06-15 Invitrogen Corp Verfahren zur herstellung von proteinen
CA2279204C (en) * 1997-01-30 2005-11-15 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2002514573A (ja) * 1998-05-08 2002-05-21 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 能動的なワクチン接種のための組成物および方法
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
DK1974747T3 (da) * 1998-08-11 2012-09-17 Biogen Idec Inc Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1949911A3 (en) 1998-11-09 2008-08-06 Biogen Idec, Inc. Treatment of chronique lymphocytic leukemia using chimeric anti-CD20 antibody.
ATE454166T1 (de) * 1998-11-09 2010-01-15 Biogen Idec Inc Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2000044225A1 (en) 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
NZ513062A (en) * 1999-01-29 2003-10-31 Smithkline Beecham HER-2/neu fusion proteins
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1187849A1 (en) * 1999-05-25 2002-03-20 Human Genome Sciences, Inc. Meth1 and meth2 polynucleotides and polypeptides
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
PT1189634E (pt) * 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
CA2383615A1 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
US20030157119A1 (en) * 1999-09-22 2003-08-21 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2801106B1 (fr) * 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
EP1568373A3 (en) * 1999-12-10 2005-12-21 Epimmune Inc. Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO2001048205A2 (en) * 1999-12-29 2001-07-05 Corixa Corporation Murine neu sequences and methods of use therefor
EP1252294A2 (en) * 2000-01-21 2002-10-30 Corixa Corporation Compounds and methods for prevention and treatment of her-2/neu associated malignancies
US6528060B1 (en) * 2000-03-16 2003-03-04 Genzyme Corporation Therapeutic compounds
ES2362715T3 (es) 2000-03-30 2011-07-12 Dendreon Corporation Composiciones y métodos para inmunoterapia a base de células dendríticas.
AU2001252262B2 (en) * 2000-04-13 2006-02-02 Biolife Science Forschungs-und Entwicklungsgesellschaft m.b.H Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
SI1282443T1 (sl) * 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
WO2002014503A2 (en) * 2000-08-14 2002-02-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
AU2001283360A1 (en) * 2000-08-14 2002-02-25 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
DE60131670T2 (de) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
AU2002220257A1 (en) * 2000-12-07 2002-06-18 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP2006510567A (ja) 2001-02-20 2006-03-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 腫瘍の治療のための細胞治療方法
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP1236740B1 (de) * 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
WO2002072766A2 (en) * 2001-03-09 2002-09-19 Board Of Regents, Universitx Of Texas System Induction of tumor immunity by variants of folate binding protein
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
ES2624854T3 (es) 2001-05-31 2017-07-17 Glaxosmithkline Biologicals Sa Partículas de replicón de alfavirus quimérico
EP1287831B1 (de) * 2001-09-03 2006-11-22 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Antigen-Mimotope und Vakzine gegen Krebserkrankungen
JP4424987B2 (ja) 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
CA2477780A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
AU2003230603A1 (en) 2002-03-08 2003-09-22 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
HRP20041037A2 (en) * 2002-04-11 2005-06-30 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
JP2006521090A (ja) 2002-07-12 2006-09-21 ザ ジョンズ ホプキンス ユニバーシティー メゾテリンワクチンおよびモデルシステム
AU2003258168B2 (en) 2002-08-12 2009-10-29 Sillajen Biotherapeutics, Inc. Methods and compositions concerning poxviruses and cancer
US20080019992A1 (en) * 2002-09-02 2008-01-24 Christoph Zielinski Antigen mimotopes and vaccine against cancerous diseases
CN1497255A (zh) * 2002-10-02 2004-05-19 ���µ�����ҵ��ʽ���� 被检测体用取样元件、被检测体处理装置及其处理方法
EP1560651A1 (en) * 2002-11-12 2005-08-10 Millipore Corporation Evaporation control device for multiwell plates
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
CA2512365A1 (en) 2003-01-03 2004-07-22 Gennaro Ciliberto Rhesus her2/neu, nucleotides encoding same, and uses thereof
WO2004067716A2 (en) * 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2004078124A2 (en) * 2003-03-03 2004-09-16 Board Of Regents, The University Of Texas System Methods and compositions involving mda-7
ES2456666T3 (es) 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
ATE546153T1 (de) * 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
CN100558894C (zh) * 2003-07-21 2009-11-11 P.安杰莱蒂分子生物学研究所 编码人表皮生长因子2/neu抗原的合成基因及其用途
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
JP2007526241A (ja) 2003-10-22 2007-09-13 フレッド ハッチンソン キャンサー リサーチ センター 細胞においてスタシスを誘導する方法、組成物、および装置
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP2290072B1 (en) 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
MX2007004079A (es) * 2004-10-06 2007-06-15 Wellstat Biologics Corp Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.
AU2005333165B2 (en) 2004-11-12 2012-07-19 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
MX2007008013A (es) * 2004-12-29 2008-02-07 Mannkind Corp Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos i-restringidos clase mhc por propositos profilacticos o terapeuticos.
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US8822535B2 (en) 2005-04-20 2014-09-02 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
CN100398558C (zh) * 2005-05-10 2008-07-02 中国人民解放军军事医学科学院基础医学研究所 HER2/neu与Herstatin相互作用的活性片段及其编码基因与应用
AU2006249199A1 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
BRPI0610267B8 (pt) 2005-05-27 2021-07-27 Oncimmune Ltd métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
CA2612394C (en) 2005-06-15 2017-02-21 The Ohio State University Research Foundation Her-2 peptides
CA2612516C (en) 2005-06-17 2015-03-24 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1933864A4 (en) * 2005-09-07 2009-12-16 Receptor Logic Ltd ANTIBODIES AS T-CELL RECEPTOR MIMICS, METHOD OF MANUFACTURE AND ITS USES
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP1934608B8 (en) * 2005-09-08 2017-07-19 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Targeted identification of immunogenic peptides
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
US7517270B2 (en) * 2006-05-30 2009-04-14 Minds-I, Inc. Construction system
US20090087873A1 (en) 2006-07-21 2009-04-02 Invitrogen Corporation Sharply resolving labeled protein molecular weight standards
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
CA2663962A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20080075528A1 (en) * 2006-09-22 2008-03-27 Michael Marzetta Construction system
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) * 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
CA2671194A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US8889143B2 (en) 2006-12-14 2014-11-18 Antigen Express, Inc. Ii-key/HER-2/neu hybrid cancer vaccine
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
US7410225B1 (en) * 2007-03-14 2008-08-12 Minds-I, Inc. Multi-part links for endless track
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2008130910A1 (en) * 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
CN105816867A (zh) * 2007-06-01 2016-08-03 亨利·M·杰克逊军事医学促进基金会 预防乳腺癌复发的疫苗
US20090017716A1 (en) * 2007-07-11 2009-01-15 Michael Marzetta Construction system
US20090061456A1 (en) * 2007-08-30 2009-03-05 Allard William J Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090117532A1 (en) * 2007-11-01 2009-05-07 Doyle Gerald V Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
US7841923B2 (en) * 2007-11-13 2010-11-30 Minds-I, Inc. Vehicle axle joint for a toy vehicle
DK2225563T3 (en) 2007-11-27 2015-02-09 Janssen Diagnostics Llc AUTOMATIC DETERMINATION AND CHARACTERIZATION OF FAN melanoma BLOOD
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090191535A1 (en) * 2007-12-22 2009-07-30 Mark Carle Connelly Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
ES2565779T3 (es) 2008-09-02 2016-04-06 Cedars-Sinai Medical Center Epítopos CD133
CA2744035C (en) 2008-12-10 2018-07-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer recurrence
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
JP5718319B2 (ja) * 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
WO2010144874A2 (en) 2009-06-12 2010-12-16 University Of Southern California Clusterin pharmaceuticals and treatment methods using the same
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
CN107303302A (zh) 2009-09-14 2017-10-31 希拉金股份有限公司 溶瘤牛痘病毒组合癌症疗法
CN102858959B (zh) 2009-12-10 2016-02-24 渥太华医院研究院 溶瘤弹状病毒
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
WO2012167382A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
US10258676B2 (en) 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
JP6170076B2 (ja) * 2012-02-17 2017-07-26 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ＨＥＲ２／ｎｅｕポリペプチドを発現する癌細胞を認識する能力を有するＣＤ８＋Ｔ細胞を作製するための方法および材料
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2013188873A1 (en) 2012-06-15 2013-12-19 Gencia Corporation Compositions and methods for enhancing immune responses
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
EP2906251B1 (en) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
TR201808051T4 (tr) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pirrolobenzodiazepin antikor konjugatları.
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
RU2684211C2 (ru) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Композиция вакцины
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
JP6474404B2 (ja) 2013-08-14 2019-02-27 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
ES2745287T3 (es) 2013-08-29 2020-02-28 Univ Texas Enzimas degradadoras de cistina/cisteína de primate genomanipuladas como agentes antineogénicos
EP3492094A1 (en) 2013-08-30 2019-06-05 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
DK3076949T3 (da) 2013-12-04 2019-11-25 Univ Texas Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
WO2016190940A1 (en) * 2015-05-22 2016-12-01 Czerniecki Brian J Manufacturing multi-dose injection ready dendritic cell vaccines
JP7080053B2 (ja) 2014-08-29 2022-06-03 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
EP3185860A4 (en) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
MX379396B (es) 2014-11-25 2025-03-11 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
EP3256490A1 (en) 2015-02-09 2017-12-20 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
RS61047B1 (sr) 2015-03-04 2020-12-31 Univ Texas Postupci za lečenje kancera sa hemizigotnim gubitkom gena tp53
JP2018515742A (ja) * 2015-03-13 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
US20180171294A1 (en) * 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
CA2988585A1 (en) 2015-06-10 2016-12-15 Raghu Kalluri Use of exosomes for the treatment of disease
RU2612015C2 (ru) * 2015-06-29 2017-03-01 Общество с ограниченной ответственностью "Сибинтех" Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы у кошек и собак
US9956172B2 (en) 2015-07-28 2018-05-01 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
RU2624862C2 (ru) * 2015-10-20 2017-07-07 Общество с ограниченной ответственностью "Эпитек" Пептид-иммуноген, используемый в терапевтической вакцине для лечения метастатического рака молочной железы
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
RS65666B1 (sr) 2015-11-09 2024-07-31 Childrens Hospital Philadelphia Glipikan 2 kao tumor marker i terapijski cilj
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
JP2019511483A (ja) 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
AU2017241440B2 (en) 2016-03-29 2024-06-27 Board Of Regents, The University Of Texas System Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP7131773B2 (ja) 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
JP7312552B2 (ja) 2016-05-16 2023-07-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ナノ粒子としてのｔＲＮＡ送達用組成物およびその使用方法
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3463438B1 (en) 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
CA3026345A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
CA3028771A1 (en) 2016-07-06 2018-01-11 Board Of Regents, The University Of Texas System Human-enzyme mediated depletion of cystine for treating patients with cystinuria
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
US9963498B2 (en) 2016-08-18 2018-05-08 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
CA3034637A1 (en) 2016-09-16 2018-03-22 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3043356A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
CN117599061A (zh) 2016-11-17 2024-02-27 得克萨斯州大学系统董事会 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN110612447B (zh) 2017-02-24 2024-02-06 德克萨斯州立大学董事会 用于检测早期胰腺癌的测定
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018209211A1 (en) 2017-05-12 2018-11-15 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
IL270503B2 (en) 2017-05-12 2024-10-01 Univ Texas Depletion of homocysteine by human enzymes for the treatment of patients with hyperhomocysteinemia and homocystinuria
JP7768666B2 (ja) 2017-05-31 2025-11-12 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
IL302943A (en) 2017-09-20 2023-07-01 Ph Pharma Co Ltd Thylanstatin analogs
EP4116327A1 (en) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
CN111601823B (zh) 2017-11-07 2024-09-24 德克萨斯大学体系董事会 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
US20200345648A1 (en) 2017-12-15 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using exosomes-associated gene editing
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
US12187799B2 (en) 2018-03-23 2025-01-07 Board Of Regents, The University Of Texas System Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor
US12134648B2 (en) 2018-03-23 2024-11-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
EP3773551B1 (en) 2018-03-27 2024-10-16 Board of Regents, The University of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
KR20200136977A (ko) 2018-03-28 2020-12-08 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀으로부터 단리된 dna에서의 후성유전학적 변화의 식별
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108624589B (zh) * 2018-04-17 2021-12-17 广州永诺生物科技有限公司 环状RNA circ-ERBB2及其检测试剂与应用
IL278044B2 (en) 2018-04-19 2024-04-01 Baylor College Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CN108715603A (zh) * 2018-06-08 2018-10-30 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108484732A (zh) * 2018-06-08 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
CN113286813A (zh) 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
US12179037B2 (en) 2018-12-11 2024-12-31 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2020163705A1 (en) 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
EP3938372B1 (en) 2019-03-15 2023-10-25 MedImmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
WO2020227711A1 (en) 2019-05-09 2020-11-12 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
EP3999546A1 (en) 2019-07-19 2022-05-25 The Children's Hospital of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
JP7781743B2 (ja) 2019-09-13 2025-12-08 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
AU2021206202A1 (en) 2020-01-07 2022-06-30 Board Of Regents, The University Of Texas System Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
KR20220132555A (ko) 2020-01-29 2022-09-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021212019A1 (en) 2020-04-17 2021-10-21 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
EP4172370A1 (en) 2020-06-30 2023-05-03 Lunglife Ai, Inc. Methods for detecting lung cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
IL302728A (en) 2020-11-13 2023-07-01 Catamaran Bio Inc Genetically modified natural killer cells and methods of use thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CA3205538A1 (en) 2021-01-19 2022-07-28 Han XIAO Bone-specific delivery of polypeptides
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
WO2023020612A1 (en) * 2021-08-20 2023-02-23 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric her2
IL311790A (en) 2021-10-05 2024-05-01 Chang Hao Ming Natural killer cells and methods of use thereof
CN113699221B (zh) * 2021-10-19 2023-10-10 广州吉赛医疗科技有限公司 HER2 mRNA及环状RNA多重荧光定量PCR检测引物探针及其应用
IL311837A (en) 2021-10-20 2024-05-01 Takeda Pharmaceuticals Co Compositions targeting bcma and methods of use thereof
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
CN114262689A (zh) * 2021-12-17 2022-04-01 上海纳米技术及应用国家工程研究中心有限公司 一种快速检测cd19/cd20-car-t细胞活性的方法
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
US20230365708A1 (en) 2022-04-01 2023-11-16 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
CA3257006A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
EP4532772A1 (en) 2022-05-24 2025-04-09 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
CA3258884A1 (en) 2022-06-10 2023-12-14 Research Development Foundation Modified FCRIIB Selective FC IGG1 Variants and Their Uses
JP2026502860A (ja) 2022-12-23 2026-01-27 ジェネンテック， インコーポレイテッド セレブロン分解剤コンジュゲートおよびその使用
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) * 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4452901A (en) * 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
EP1006194A3 (en) * 1989-08-04 2008-07-02 Triton Biosciences Inc. C-erbB-2 external domain: GP75
ES2070492T3 (es) * 1990-01-26 1995-06-01 Washington Res Found Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos.
US5958784A (en) * 1992-03-25 1999-09-28 Benner; Steven Albert Predicting folded structures of proteins
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Also Published As

Publication number Publication date
US7655239B2 (en) 2010-02-02
PT817846E (pt) 2005-11-30
US20040082758A1 (en) 2004-04-29
US6664370B2 (en) 2003-12-16
JP2008056679A (ja) 2008-03-13
US5726023A (en) 1998-03-10
JP4510147B2 (ja) 2010-07-21
RU2236461C2 (ru) 2004-09-20
CZ309697A3 (cs) 1998-01-14
DE69634912T2 (de) 2006-04-20
US5876712A (en) 1999-03-02
CN1183117A (zh) 1998-05-27
US6075122A (en) 2000-06-13
EP1418235A3 (en) 2004-08-11
AU5522296A (en) 1996-10-16
CA2216601A1 (en) 1996-10-03
WO1996030514A1 (en) 1996-10-03
EP0817846B1 (en) 2005-07-06
US7247703B2 (en) 2007-07-24
EP1418235A2 (en) 2004-05-12
EP0817846A1 (en) 1998-01-14
MX9707501A (es) 1998-06-30
HUP9801826A3 (en) 2000-12-28
CN1951398A (zh) 2007-04-25
KR100554186B1 (ko) 2007-04-11
NO974502D0 (no) 1997-09-29
AU708237B2 (en) 1999-07-29
US20020055614A1 (en) 2002-05-09
ES2245783T3 (es) 2006-01-16
ATE299180T1 (de) 2005-07-15
CA2216601C (en) 2002-10-22
US5801005A (en) 1998-09-01
DE69634912D1 (de) 2005-08-11
KR19980703453A (ko) 1998-11-05
HUP9801826A2 (hu) 1998-11-30
RU2004115492A (ru) 2005-11-10
JPH11502710A (ja) 1999-03-09
US20080076904A1 (en) 2008-03-27
US20100087621A1 (en) 2010-04-08
NO321941B1 (no) 2006-07-24
NO20061723L (no) 1996-10-01
CZ296618B6 (cs) 2006-05-17
US5846538A (en) 1998-12-08
CZ296617B6 (cs) 2006-05-17
DK0817846T3 (da) 2005-11-07
BR9607889A (pt) 1999-08-10
NZ306616A (en) 2001-03-30
CN1150318C (zh) 2004-05-19
CN1597953A (zh) 2005-03-23

Similar Documents

Publication Publication Date Title
NO974502D0 (no) Intercellulært domene av HER-2/neu-protein for forhindring eller behandling av malignitet
MXPA01007721A (es) Proteinas de fusion her-2/neu.
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
EP0709090A3 (en) Compositions for the treatment of resistant tumors
DE69534702D1 (de) Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
KR900700469A (ko) 우레탄-보호된 아미노산-n-카르복시무수물
PT662137E (pt) Transcricao de genes e radiacao ionizante: metodos e composicoes
DE69332520D1 (de) Nukleinsäure, expressionsvektor und zusammensetzungen zur identifizierung und herstellung von rekombinanten sialyltransferasen
DE69326559D1 (de) Rekombinante methode und wirt zur herstellung von xylitol
DE69411122D1 (de) Verfahren zur Herstellung von Epoxigruppen-enthaltenden Polysiloxanen
GR3032804T3 (en) Gp75 as a tumor vaccine for melanoma.
ATE190659T1 (de) Rekombinante immuntoxine
ATE206129T1 (de) Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
DE69333992D1 (de) Verfahren zur herstellung eines sets von kombinatorischen polypeptidantigenen
DE59010723D1 (de) Verwendung kohlenwasserstoffreicher Gele als Fracturing-Flüssigkeiten
ATE187738T1 (de) Verfahren zur identifizierung und herstellung von bindungsstellen aufeinanderwirkender proteine
DE68924788D1 (de) Verfahren zur Herstellung von Imid-Bindungen enthaltenden Harzen und diese Harze enthaltende Flammenschutzmittel.
ES2098435T3 (es) Agentes antitumorales de tioxantenona.
SE9604439D0 (sv) New receptor
EP0970187A4 (en) DIFFERENTIATION FACTOR OF HYPOPHYSIS AND METHODS FOR ITS USE.
DE69013576D1 (de) Verfahren zur Herstellung von Imidbindungen enthaltenden Harzen.
ATE92629T1 (de) Verfahren zur unmittelbaren bestimmung physikalischer eigenschaften von kohlenwasserstoffprodukten.
ATE9851T1 (de) Verfahren zur verhinderung erfolgreicher faelschungen von dokumenten und anordnung zur durchfuehrung des verfahrens.